Exodus Point Capital Management, LP Viridian Therapeutics, Inc.\De Transaction History
Exodus Point Capital Management, LP
- $14.6 Billion
- Q4 2024
A detailed history of Exodus Point Capital Management, LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 25,724 shares of VRDN stock, worth $437,822. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,724Holding current value
$437,822% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding VRDN
# of Institutions
193Shares Held
78.5MCall Options Held
575KPut Options Held
441K-
Black Rock Inc. New York, NY4.77MShares$81.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$78.2 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$77 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$66.1 Million9.15% of portfolio
-
State Street Corp Boston, MA3.52MShares$60 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $679M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...